Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
Genmab and ADC Therapeutics have amended their agreement to further develop camidanlumab tesirine (Cami), an antibody-drug conjugate targeting CD25. Originally established in 2013, the collaboration aims to enhance Cami's commercialization prospects following positive Phase 1 clinical trial results showing an 86.5% overall response rate in Hodgkin lymphoma patients. ADC Therapeutics is currently conducting a pivotal Phase 2 trial with over 50% enrollment, anticipating interim results in H1 2021. Under the new terms, Genmab will receive a tiered royalty on net sales instead of a divestment opportunity.
ADC Therapeutics SA (NYSE: ADCT) announced that underwriters of its upsized public offering, which closed on September 28, 2020, fully exercised their option to purchase an additional 900,000 common shares at $34 each. The company did not receive proceeds from this sale. Morgan Stanley, BofA Securities, and Cowen served as joint book-running managers. ADC Therapeutics focuses on developing antibody drug conjugates for hematological malignancies and solid tumors, with lead candidates Loncastuximab tesirine and Camidanlumab tesirine currently in pivotal clinical trials.
ADC Therapeutics has announced the pricing of its initial public offering (IPO) of 12,245,631 shares at $19.00 per share, aiming for $232.7 million in gross proceeds. Trading is set to begin on the New York Stock Exchange under the ticker symbol ADCT on May 15, 2020, with the offering closing on May 19, 2020. The underwriters have a 30-day option to purchase an additional 1,836,844 shares. ADC Therapeutics focuses on developing targeted antibody drug conjugates for treating hematological malignancies and solid tumors.